نشریات بند

جاری کہانی · 1 رپورٹ

Novo Nordisk's lawsuit over Eli Lilly GLP-1 ads

پہلی بار نشر ہوا تازہ ترین نشریہ

جاری ہےاگلی جانچ : Further court proceedings or a resolution of the case.

صورتِ حال

Novo Nordisk has sued Eli Lilly in federal court, alleging its direct-to-consumer GLP-1 drug ads make false and misleading dosing comparisons; Lilly says the ads are truthful. No court ruling, settlement or other resolution is reported, so the case remains open.

خبر ٹریکردن 1

1 رپورٹ11 ذرائع ابلاغ11 ماخذ1 ویڈیو

  • ابھی کوئی تاریخ والا واقعہ نہیں
    1. اپ ڈیٹ 1Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

    خبر اب تک

    1. اپ ڈیٹ 1

      Four Drugs, One Courtroom: Novo Nordisk Takes Eli Lilly to Trial Over GLP-1 Ads

      A New Jersey federal complaint says Lilly's Zepbound and Mounjaro ads stack the dosing deck against Wegovy and Ozempic. The market they share is reshaping the industry.

      اس رپورٹ کے بعد بھی حل طلب

      • Any verbatim Lilly on-the-record statement beyond the general "truthful and based on the best available scientific evidence" framing. The source file does not include one.
      • How the court will treat the question of which doses are properly comparable, and which clinical trials it considers current.
      • Whether the case produces a settlement, a ruling on the injunction, or a long discovery fight.

    تاریخچہ

    1. شروع ہوئی1 رپورٹ

    کون شامل ہے

    مقامات

    • CopenhagenCopenhagen, Denmark1 رپورٹ
    • IndianapolisIndianapolis, IN, USA1 رپورٹ
    • US District Court for the District of New Jersey50 Walnut St #4015, Newark, NJ 07102, USA1 رپورٹ

    اس خبر پر ہم نے جتنے ذرائع ابلاغ پڑھے

    11 ماخذ11 ذرائع ابلاغ1 ویڈیو